Research Article
Multiple Myeloma Patients at Various Cytogenetic Risks Benefit Differently from Autologous Stem Cell Transplantation as a Consolidation Therapy
Figure 5
Comparison of PFS in the patients of ASCT group and non-ASCT group in the intermediate-risk subgroup. The median PFS was 25.7 versus 15.1 months with no significant difference ().